Meningococcal group A, C, W-135 and Y conjugate vaccine (Men ACWY) 2026-2027 (2028, 2029)

The Ministry of Social Affairs and Health (later referred to as ”STM”) and the Finnish Institute for Health and Welfare (later referred to as "THL" or “Customer” ) request your tender for Meningococcal group A, C, W-135 and Y conjugate vaccine, required for the vaccinations in the Finnish Defence Forces …

CPV: 33651600 Cjepiva, 33600000 Farmaceutski proizvodi, 33650000 Opća protuupalna sredstva za sustavno liječenje, cjepiva, antineoplastična sredstva i imunomodulatori
mjesto izvršenja:
Meningococcal group A, C, W-135 and Y conjugate vaccine (Men ACWY) 2026-2027 (2028, 2029)
registar:
Ministry of Social Affairs and Health
nagradni broj:
THL/842/2.02.06/2025

1. Buyer

1.1 Buyer

Official name : Ministry of Social Affairs and Health
Legal type of the buyer : Central government authority
Activity of the contracting authority : Health

2. Procedure

2.1 Procedure

Title : Meningococcal group A, C, W-135 and Y conjugate vaccine (Men ACWY) 2026-2027 (2028, 2029)
Description : The Ministry of Social Affairs and Health (later referred to as ”STM”) and the Finnish Institute for Health and Welfare (later referred to as "THL" or “Customer” ) request your tender for Meningococcal group A, C, W-135 and Y conjugate vaccine, required for the vaccinations in the Finnish Defence Forces and the Finnish Border Guard and for the risk group vaccinations in the National Vaccination Programme in Finland. The contract period is two years 2026 - 2027. The procurement contains two one-year contract period renewals (1 + 1) to extend the contract for the periods 2028 and 2029. Estimated quantity for the contract period including contract period renewals is 112,000 doses. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The most economically advantageous Tender shall be a Tender with lowest price. Please note that all times given in the Call for Tender refer to local time in Finland. Call for Tenders, annexes: Annex 1 Contract Annex 2 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 3 Delivery schedule Annex 4 Subcontractors Annex 5 Description of the Handi Service
Procedure identifier : 0d29fa69-8363-4595-b14b-9d16508892e0
Previous notice : f643a803-bec6-417c-80a4-f3a09dc5e4dc-01
Internal identifier : THL/842/2.02.06/2025
Type of procedure : Open
The procedure is accelerated : no
Main features of the procedure : An open procedure is applied. The procurement will take place in compliance with the Directive 2014/24/EU on public procurement and the Finnish Act on Public Procurement and Concession Contracts (1397/2016). The estimated value of the procurement will exceed the EU threshold value. In case none of the tenders received meets the requirements of the Call for Tender as intended by the Customer, or if conditions change during the procurement process so that the Customer will be unable to make use of the results of the competitive bidding, the Customer may interrupt the procurement procedure. No compensation will be paid to the tenderers for preparing a tender, presenting it or other participations in the procedure. The Call for Tender documents are available in English.

2.1.1 Purpose

Main nature of the contract : Supplies
Main classification ( cpv ): 33651600 Vaccines
Additional classification ( cpv ): 33600000 Pharmaceutical products
Additional classification ( cpv ): 33650000 General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents

2.1.2 Place of performance

Country subdivision (NUTS) : Helsinki-Uusimaa ( FI1B1 )
Country : Finland

2.1.4 General information

Additional information : The purpose of STM and the Customer is to procure Meningococcal group A, C, W-135 and Y conjugate vaccine required for the vaccinations in the Finnish Defence Forces and the Finnish Border Guard and for the risk group vaccinations in the National Vaccination Programme in Finland. The tendered vaccine must be suitable for adults and children according to Article´s Summary of Product Characteristics (SPC). The Customer should prefer syringes without fixed needles. This procurement is not divided into lots. According to Communicable Diseases Act (1227/2016) the Finnish Institute for Health and Welfare has an obligation to supervise the implementation of the national immunization programme and other general vaccinations and monitor the implementation and impact of the vaccinations. Implementing and supervising the implementation of the national immunization programme is practical with one suitable vaccine. In addition pursuant to Section 2 of the Act on Public Procurement and Concession Contracts (Procurement Act), the contracting entity seeks to enhance efficiency in the use of public funds and arrange their procurement operations so that procurements can be implemented with optimal economy, quality and orderliness, taking advantage of existing competitive conditions and allowing for environmental and social aspects. These fundamental aims will be achieved by procuring one suitable vaccine for all target groups. The target groups for the Meningococcal group A, C, W-135 and Y conjugate vaccine are the conscripts in the Finnish Defence Forces and the Finnish Border Guard and the medical risk groups in the National Vaccination Programme. More information about National Vaccination Programme and vaccinations can be found on the website of the Finnish Institute for Health and Welfare: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The subject of procurement and the mandatory requirements relating to it are described in detail in this Call for Tender and its annexes. The contract will be awarded to one Supplier based on a comparison of tenders. If the Supplier has modified vaccine available/releases a modified vaccine during the contract period, the Parties may agree to substitute the Article with the modified vaccine. In case of substitution, all terms and prices in the Contract shall apply without modification. CONTRACT PERIOD The Contract shall enter into a force once the competent signatories of both the Contracting Parties have duly signed the Contract. The Contract shall expire when all contractual duties and obligations have been performed by both Parties. However, the contract period shall be counted from the first day of the month on which the Supplier has handed over the first delivery of the Articles to the Customer´s pharmaceutical wholesaler. The Contract period is two (2) years from the date defined previously above and the estimated quantity to be purchased for this period is 56,000 +/- 20% doses. After the contract period, the Customer reserves the right for the contract period renewals described in section "Description of renewals". Tenders will be compared in the manner described in section "Grounds for decision" of the Call for Tenders.
Legal basis :
Directive 2014/24/EU

5. Lot

5.1 Lot technical ID : LOT-0000

Title : Meningococcal group A, C, W-135 and Y conjugate vaccine (Men ACWY) 2026-2027 (2028, 2029)
Description : The Ministry of Social Affairs and Health (later referred to as ”STM”) and the Finnish Institute for Health and Welfare (later referred to as "THL" or “Customer” ) request your tender for Meningococcal group A, C, W-135 and Y conjugate vaccine, required for the vaccinations in the Finnish Defence Forces and the Finnish Border Guard and for the risk group vaccinations in the National Vaccination Programme in Finland. The contract period is two years 2026 - 2027. The procurement contains two one-year contract period renewals (1 + 1) to extend the contract for the periods 2028 and 2029. Estimated quantity for the contract period including contract period renewals is 112,000 doses. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The most economically advantageous Tender shall be a Tender with lowest price. Please note that all times given in the Call for Tender refer to local time in Finland. Call for Tenders, annexes: Annex 1 Contract Annex 2 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 3 Delivery schedule Annex 4 Subcontractors Annex 5 Description of the Handi Service
Internal identifier : THL/842/2.02.06/2025

5.1.1 Purpose

Main nature of the contract : Supplies
Main classification ( cpv ): 33651600 Vaccines
Additional classification ( cpv ): 33600000 Pharmaceutical products
Additional classification ( cpv ): 33650000 General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents

5.1.2 Place of performance

Country subdivision (NUTS) : Helsinki-Uusimaa ( FI1B1 )
Country : Finland
Additional information :

5.1.3 Estimated duration

Duration : 24 Month

5.1.4 Renewal

Maximum renewals : 2
Other information about renewals : After the Contract period, THL shall reserve a right for two (2) one (1)-year Contract period renewals (1+1). THL should extend the Contract period with one (1) or two (2) contract period renewals at a time. If THL decides to exercise the Contract period renewal, the Supplier shall commit to the following extensions of the Contract: The Contract consists of contract period renewals for the years 2028 and 2029. Estimated quantity for one contract period renewal is 28,000 doses (+/- 20%).

5.1.6 General information

Procurement Project not financed with EU Funds.
The procurement is covered by the Government Procurement Agreement (GPA) : yes
Additional information : The purpose of STM and the Customer is to procure Meningococcal group A, C, W-135 and Y conjugate vaccine required for the vaccinations in the Finnish Defence Forces and the Finnish Border Guard and for the risk group vaccinations in the National Vaccination Programme in Finland. The tendered vaccine must be suitable for adults and children according to Article´s Summary of Product Characteristics (SPC). The Customer should prefer syringes without fixed needles. This procurement is not divided into lots. According to Communicable Diseases Act (1227/2016) the Finnish Institute for Health and Welfare has an obligation to supervise the implementation of the national immunization programme and other general vaccinations and monitor the implementation and impact of the vaccinations. Implementing and supervising the implementation of the national immunization programme is practical with one suitable vaccine. In addition pursuant to Section 2 of the Act on Public Procurement and Concession Contracts (Procurement Act), the contracting entity seeks to enhance efficiency in the use of public funds and arrange their procurement operations so that procurements can be implemented with optimal economy, quality and orderliness, taking advantage of existing competitive conditions and allowing for environmental and social aspects. These fundamental aims will be achieved by procuring one suitable vaccine for all target groups. The target groups for the Meningococcal group A, C, W-135 and Y conjugate vaccine are the conscripts in the Finnish Defence Forces and the Finnish Border Guard and the medical risk groups in the National Vaccination Programme. More information about National Vaccination Programme and vaccinations can be found on the website of the Finnish Institute for Health and Welfare: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The subject of procurement and the mandatory requirements relating to it are described in detail in this Call for Tender and its annexes. The contract will be awarded to one Supplier based on a comparison of tenders. If the Supplier has modified vaccine available/releases a modified vaccine during the contract period, the Parties may agree to substitute the Article with the modified vaccine. In case of substitution, all terms and prices in the Contract shall apply without modification. CONTRACT PERIOD The Contract shall enter into a force once the competent signatories of both the Contracting Parties have duly signed the Contract. The Contract shall expire when all contractual duties and obligations have been performed by both Parties. However, the contract period shall be counted from the first day of the month on which the Supplier has handed over the first delivery of the Articles to the Customer´s pharmaceutical wholesaler. The Contract period is two (2) years from the date defined previously above and the estimated quantity to be purchased for this period is 56,000 +/- 20% doses. After the contract period, the Customer reserves the right for the contract period renewals described in section "Description of renewals". Tenders will be compared in the manner described in section "Grounds for decision" of the Call for Tenders.

5.1.10 Award criteria

Criterion :
Type : Price
Description : The cheapest price
Category of award weight criterion : Fixed value (total)
Award criterion number : 100

5.1.15 Techniques

Framework agreement :
No framework agreement
Information about the dynamic purchasing system :
No dynamic purchase system

5.1.16 Further information, mediation and review

Review organisation : Markkinaoikeus
Information about review deadlines : The procurement contract can be signed no earlier than 14 days from the time the tenderer has been informed, or is considered to have been informed, of the procurement decision and its grounds (=stand-still period).

6. Results

Value of all contracts awarded in this notice : 2 485 056 Euro

6.1 Result lot ldentifier : LOT-0000

At least one winner was chosen.

6.1.2 Information about winners

Winner :
Official name : GlaxoSmithKline Oy
Tender :
Tender identifier : tenderReference-4300414-856683
Identifier of lot or group of lots : LOT-0000
Value of the tender : 2 485 056 Euro
Subcontracting : No
Contract information :
Identifier of the contract : THL/842/2.02.06/2025
Date on which the winner was chosen : 18/06/2025
Date of the conclusion of the contract : 04/09/2025

6.1.4 Statistical information

Received tenders or requests to participate :
Type of received submissions : Tenders submitted electronically
Number of tenders or requests to participate received : 2

8. Organisations

8.1 ORG-0001

Official name : Markkinaoikeus
Registration number : 3006157-6
Postal address : Radanrakentajantie 5
Town : Helsinki
Postcode : 00520
Country subdivision (NUTS) : Helsinki-Uusimaa ( FI1B1 )
Country : Finland
Telephone : +358 295643300
Roles of this organisation :
Review organisation

8.1 ORG-0002

Official name : Ministry of Social Affairs and Health
Registration number : 0244685-8
Postal address : P.O. BOX 33
Town : Helsinki
Postcode : 00023
Country subdivision (NUTS) : Helsinki-Uusimaa ( FI1B1 )
Country : Finland
Contact point : Hankintayksikkö
Telephone : +358 295246000
Roles of this organisation :
Buyer

8.1 ORG-0003

Official name : GlaxoSmithKline Oy
Size of the economic operator : Large
Registration number : 0108378-4
Postal address : Porkkalankatu 20 A
Town : Helsinki
Postcode : 00180
Country subdivision (NUTS) : Helsinki-Uusimaa ( FI1B1 )
Country : Finland
Roles of this organisation :
Tenderer
Winner of these lots : LOT-0000

8.1 ORG-0004

Official name : Hansel Oy (Hilma)
Registration number : FI09880841
Postal address : Mannerheiminaukio 1a
Town : Helsinki
Postcode : 00100
Country subdivision (NUTS) : Helsinki-Uusimaa ( FI1B1 )
Country : Finland
Contact point : eSender
Telephone : 029 55 636 30
Roles of this organisation :
TED eSender

Notice information

Notice identifier/version : 74ae1555-1cf3-4efd-b687-61944aeb876c - 01
Form type : Result
Notice type : Contract or concession award notice – standard regime
Notice dispatch date : 25/09/2025 10:33 +00:00
Notice dispatch date (eSender) : 25/09/2025 10:33 +00:00
Languages in which this notice is officially available : English
Notice publication number : 00632153-2025
OJ S issue number : 185/2025
Publication date : 26/09/2025